Vancomycin Hydrochloride is a drug owned by Xellia Pharmaceuticals Aps. It is protected by 5 US drug patents filed from 2020 to 2023 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Nov 06, 2035. Details of Vancomycin Hydrochloride's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US10188697 | Glycopeptide compositions |
Nov, 2035
(11 years from now) | Active |
| US10039804 | Glycopeptide compositions |
Nov, 2035
(11 years from now) | Active |
| US11517609 | Glycopeptide compositions |
Nov, 2035
(11 years from now) | Active |
| US10849956 | Glycopeptide compositions |
Nov, 2035
(11 years from now) | Active |
| US11628200 | Glycopeptide compositions |
Nov, 2035
(11 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Vancomycin Hydrochloride's patents.
Latest Legal Activities on Vancomycin Hydrochloride's Patents
Given below is the list of recent legal activities going on the following patents of Vancomycin Hydrochloride.
| Event | Date | Patent/Publication |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Year, Large Entity | 15 May, 2024 | US10849956 |
| Electronic Review | 19 May, 2023 | US11628200 |
| Email Notification | 19 May, 2023 | US11628200 |
| Miscellaneous Communication to Applicant - No Action Count | 18 May, 2023 | US11628200 |
| Mail Miscellaneous Communication to Applicant | 18 May, 2023 | US11628200 |
| Electronic Review | 21 Apr, 2023 | US11628200 |
| Email Notification | 21 Apr, 2023 | US11628200 |
| Mail Miscellaneous Communication to Applicant | 21 Apr, 2023 | US11628200 |
| Miscellaneous Communication to Applicant - No Action Count | 18 Apr, 2023 | US11628200 |
| Patent Issue Date Used in PTA Calculation | 18 Apr, 2023 | US11628200 |
Several oppositions have been filed on Vancomycin Hydrochloride's European patents. EP oppositions can significantly impact the timeline for the generic launch of drugs. If an opposition results in the revocation or amendment of a patent, it can shorten the exclusivity period of the original drug. This can lead to an earlier entry of generic versions into the market. To help you estimate the potential early arrival of Vancomycin Hydrochloride's generic, the next section provides detailed information on ongoing and past EP oppositions related to Vancomycin Hydrochloride patents.
Vancomycin Hydrochloride's oppositions filed in EPO
Vancomycin Hydrochloride has faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Oct 01, 2020, by Df-Mp Dörries Frank-Molnia & Pohlman Patentanwälte Rechtsanwälte Parg Mbb. This opposition was filed on patent number EP15791287A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
 | |||
| EP15791287A | Oct, 2020 | df-mp Dörries Frank-Molnia & Pohlman Patentanwälte Rechtsanwälte ParG mbB | Revoked |
US patents provide insights into the exclusivity only within the United States, but Vancomycin Hydrochloride is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Vancomycin Hydrochloride's family patents as well as insights into ongoing legal events on those patents.
Vancomycin Hydrochloride's family patents
Coming Soon
Patent Strength Analyzer
YesNo
Thank you for your response 🥳
Generic Launch
Generic Release Date:
Vancomycin Hydrochloride's generic launch date based on the expiry of its last outstanding patent is estimated to be Nov 06, 2035 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Vancomycin Hydrochloride Generics:
Vancomycin Hydrochloride is the generic name for the brand Vancomycin Hydrochloride. 32 different companies have already filed for the generic of Vancomycin Hydrochloride, with Hikma having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Vancomycin Hydrochloride's generic
About Vancomycin Hydrochloride
Vancomycin Hydrochloride is a drug owned by Xellia Pharmaceuticals Aps. It is used for treating bacterial infections. Vancomycin Hydrochloride uses Vancomycin Hydrochloride as an active ingredient. Vancomycin Hydrochloride was launched by Xellia Pharms Aps in 2019.
Market Authorisation Date:
Vancomycin Hydrochloride was approved by FDA for market use on 15 February, 2019.
Active Ingredient:
Vancomycin Hydrochloride uses Vancomycin Hydrochloride as the active ingredient. Check out other Drugs and Companies using Vancomycin Hydrochloride ingredient
Treatment:
Vancomycin Hydrochloride is used for treating bacterial infections.
Dosage:
Vancomycin Hydrochloride is available in solution form for intravenous use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| EQ 1.5GM BASE/300ML (EQ 5MG BASE/ML) | SOLUTION | Prescription | INTRAVENOUS |
| EQ 2GM BASE/400ML (EQ 5MG BASE/ML) | SOLUTION | Prescription | INTRAVENOUS |
| EQ 500MG BASE/100ML (EQ 5MG BASE/ML) | SOLUTION | Prescription | INTRAVENOUS |
| EQ 750MG BASE/150ML (EQ 5MG BASE/ML) | SOLUTION | Prescription | INTRAVENOUS |
| EQ 1.25GM BASE/250ML (EQ 5MG BASE/ML) | SOLUTION | Prescription | INTRAVENOUS |
| EQ 1.75GM BASE/350ML (EQ 5MG BASE/ML) | SOLUTION | Prescription | INTRAVENOUS |
| EQ 1GM BASE/200ML (EQ 5MG BASE/ML) | SOLUTION | Prescription | INTRAVENOUS |